Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
25 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
8-K
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
23 Apr 24
PRE 14A
Preliminary proxy
10 Apr 24
8-K
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
2 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
8-K
Practice Statement Letter
29 Mar 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
28 Feb 24
8-K
Kiniksa Pharmaceuticals Provides Corporate Update
4 Jan 24
UPLOAD
Letter from SEC
2 Jan 24
CORRESP
Correspondence with SEC
8 Dec 23
CORRESP
Correspondence with SEC
21 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
31 Oct 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
25 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
2 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
2 Mar 23
10-K
2022 FY
Annual report
2 Mar 23
8-K
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
28 Feb 23
8-K
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
9 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
1 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
3 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
30 Jun 22
EFFECT
Notice of effectiveness
18 May 22
EFFECT
Notice of effectiveness
18 May 22
Latest ownership filings
4
Mark Ragosa
30 Apr 24
4
Sanj K Patel
8 Apr 24
4
John F. Paolini
8 Apr 24
4
Mark Ragosa
8 Apr 24
4
Ross Moat
8 Apr 24
4
Michael R Megna
8 Apr 24
4
Eben Tessari
8 Apr 24
SC 13G/A
BlackRock Inc.
5 Apr 24
4
Mark Ragosa
3 Apr 24
4
Eben Tessari
3 Apr 24
4
Sanj K Patel
3 Apr 24
4
Michael R Megna
3 Apr 24
4
Ross Moat
3 Apr 24
4
John F. Paolini
3 Apr 24
4
Sanj K Patel
11 Mar 24
4
Sanj K Patel
6 Mar 24
4
Eben Tessari
5 Mar 24
4
John F. Paolini
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Michael R Megna
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
John F. Paolini
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
SC 13G/A
HHLR ADVISORS, LTD.
14 Feb 24
SC 13G/A
Fairmount Funds Management LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
Rubric Capital Management LP
12 Feb 24
SC 13G
BlackRock Inc.
25 Jan 24
4
Mark Ragosa
4 Jan 24
4
Michael R Megna
4 Jan 24
144
Notice of proposed sale of securities
3 Jan 24
4
Michael R Megna
21 Dec 23
144
Notice of proposed sale of securities
19 Dec 23
4
John F. Paolini
11 Dec 23
144
Notice of proposed sale of securities
7 Dec 23
4
Richard S Levy
7 Nov 23
4
Michael R Megna
6 Oct 23
4
Michael R Megna
6 Sep 23
4
Ross Moat
6 Sep 23